An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of Olinciguat (IW-1701)
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs Olinciguat (Primary) ; Itraconazole
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Cyclerion Therapeutics
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2019 Status changed from not yet recruiting to recruiting.